Spanish drugmaker Grifols SA paid a higher price to buy blood plasma from an entity linked to its controlling family than ...

Spanish plasma-derived medicines specialist Grifols (MCE: GRF) announced that the positive Phase III study data on its fibrinogen concentrate, BT524, has been published in eClinicalMedicine, a ...

The global acute on chronic liver failure (ACLF) market is witnessing a transformation with a focus on innovative solutions like gene therapies and r ...

Detailed price information for Grifols S.A. ADR (GRFS-Q) from The Globe and Mail including charting and trades.

Dreieich, 23 June 2025. Biotest today announces that the positive Phase III study data on its fibrinogen concentrate, BT524, has been published in eClinicalMedicine, a peer-reviewed journal published ...

Plasma, by the way, is the liquid part of blood and is a vital input into our health-care system. While some is used directly ...

Get the latest Grifols, S.A. (GRFS) stock news and headlines to help you in your trading and investing decisions.

This risk is compounded by Grifols' own plans to expand its collection network to 520 by 2026 compared with CSL's current network of roughly 300.

The City of Bowling Green Parks and Recreation Department, in partnership with title sponsor B.G. Transit and supporting ...

Private equity firm Brookfield has said it is withdrawing from negotiations to take over Grifols, sparking a slump in the Spanish pharma group's share price. The Canadian investment group said it ...

Grifols has filed for US approval of its new drug for rare bleeding disorder acquired fibrinogen deficiency (AFD), aiming for a first-in-class launch.